Who can join
Studies for children and teens
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
468 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
AstraZeneca
- Location
- Anchorage, AK + 70 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- Loma Linda, CA + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Pfizer
- Location
- Birmingham, AL + 6 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 1
Safety, PK and PD of FLQ-101 in Premature Neonates
FELIQS INC.
- Location
- Austin, TX
- Eligibility basics
- Ages 0 mo–0 mo
- RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC
- Location
- Birmingham, AL + 20 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 3
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
Boehringer Ingelheim
- Location
- Boston, MA
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
AstraZeneca
- Location
- Bakersfield, CA + 11 other US sites
- Eligibility basics
- Ages 4–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Eli Lilly and Company
- Location
- Oxnard, CA
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Takeda
- Location
- Oklahoma City, OK
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Huntsville, AL + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Incyte Corporation
- Location
- Duarte, CA + 6 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- Birmingham, AL + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
argenx
- Location
- Little Rock, AR + 10 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
Ionis Pharmaceuticals, Inc.
- Location
- Birmingham, AL + 4 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company
- Location
- Hartford, CT + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Eli Lilly and Company
- Location
- Morehead City, NC
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2/Phase 3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Merck Sharp & Dohme LLC
- Location
- Wilmington, DE + 7 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent…
Bausch Health Americas, Inc.
- Location
- Mobile, AL + 22 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Hoffmann-La Roche
- Location
- Loma Linda, CA + 8 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Huntsville, AL + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
- Location
- Aurora, CO + 7 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb
- Location
- Anaheim, CA + 12 other US sites
- Eligibility basics
- Ages 13–17
Questions
If I fit this group, will I qualify?
Not necessarily. Age and sex limits are only the first filter. Each study has its own inclusion and exclusion criteria, and the research team decides at screening.
Where do these age and sex limits come from?
From the eligibility section of each study’s official ClinicalTrials.gov record. We don’t infer eligibility from anything else.